MEDICAL RESEARCH INSTITUTES ASSOCIATION RESPONDS TO DRAFT NATIONAL RESEARCH STRATEGY National workforce plan welcomed, though concern remains on the indirect costs of research
With
Dr Saraid Billiards,
Chief Executive Officer
Association of Australian Medical Research Institutes (AAMRI)
SEGMENT
Filmed in Melbourne | October 2025
On 27 August 2025, the Minister for Health, Disability and Ageing announced the release of the draft National Health and Medical Research Strategy (the National Strategy).
The aims of the National Strategy are to build on Australia’s strengths in health and medical research and leverage Australia’s world leading research capability.
The developed strategy aims to attract researchers and investors, strengthen coordination and impact and improve health outcomes in communities.
Involved in the initial consultation phase, was the Association of Australian Medical Research Institutes (AAMRI), the peak body for medical research institutes across Australia. Member institutes work on a broad spectrum of human health issues such as preventive health, chronic disease, mental health, immunology and Indigenous health. Their research ranges from fundamental biomedical discovery through to clinical research and the translation of research findings.
AAMRI CEO Dr Saraid Billiards has been working Health, Ageing and Disability Minister, The Hon Mark Butler MP, his office and subsequently with Ms Rosemary Huxtable AO, who in November 2024 was appointed to develop the National Health and Medical Research Strategy.
Australian Health Journal spoke with Dr Billiards about the advocacy work of AAMRI, the reviews, reports, announcements and Phase 1 consultation period leading to the draft release. Consultation on the draft Strategy is open until 8 October 2025.
Source: Adapted from AAMRI release, NHMRC news story and Department of Health, Disability & Aged Care website.
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Artificial Intelligence (AI) in clinical trials and clinical care
Australian Health Journal today continues a major episode release on Technology Aided Healthcare Delivery, with part 2 on Artificial Intelligence in trials and clinical care. Interviews were captured at AI, Machine Learning & Robotics in Health conference in October organised by Informa Australia.
-
Integrating oral health care across non-dental professionals
Poor oral health can contribute to or exacerbate several systemic health conditions due to the close connection between oral bacteria, inflammation, and systemic processes. These conditions include cardiovascular health, diabetes, respiratory health, cognitive health, pregnancy and birth outcomes.
